iBio (IBIO) Fundamental Analysis: Revenue, Earnings & Valuation

1.40 / 10

Underperform

Fundamental analysis rates IBIO as Underperform with a 1.4/10 score. Key metrics are negative: ROE –135%, diluted ROE –117%, and poor profit growth. Equity multiplier (1.35) offers slight upside, but overall financial health is challenging.

Analysis Checks(1/6)

Annualized return on equity (%)

Value-135.71

Score1/3

Weight10.20%

1M Return-1.24%

Equity multiplier

Value1.35

Score2/3

Weight9.30%

1M Return-1.08%

Total profit (YoY growth rate %)

Value47.31

Score0/3

Weight29.14%

1M Return-3.50%

ROE (diluted) (%)

Value-116.80

Score0/3

Weight26.70%

1M Return-3.16%

ROE (%)

Value-135.71

Score1/3

Weight10.20%

1M Return-1.24%

Net profit attributable to parent company shareholders (YoY growth rate %)

Value61.69

Score1/3

Weight14.46%

1M Return-1.60%

Is IBIO undervalued or overvalued?

IBIO scores 1.40/10 on fundamentals and holds a Premium valuation at present. Backed by its -41.19% ROE, -8245.67% net margin, -2.75 P/E ratio, 1.20 P/B ratio, and -158.48% earnings growth, these metrics solidify its Underperform investment rating.